Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATAI LIFE SCIENCES N.V.

(ATAI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Atai Life Sciences and Introspect Digital Therapeutics to Test Novel Digital Therapeutic Approach in Patients Receiving Ketamine for Treatment Resistant Depression

09/09/2021 | 04:30pm EDT

atai Life Sciences and its digital therapeutic platform Introspect Digital Therapeutics, Inc.(“Introspect”), announced a usability study of Introspect’s digital therapeutic (DTx) app technology in support of standard of care ketamine therapy for patients with treatment resistant depression (TRD) in collaboration with Kadima Neuropsychiatry. TRD impacts 100 million people globally, close to a third of the 300 million diagnosed with depression, many of whom are geographically restricted in their ability to access in-person psychological care. Introspect’s DTx app approach to supported treatment in mental health will be integrated across 3 cohorts, with Cohort 1 focusing on user acceptability, Cohort 2 examining the introduction of therapeutic content via the app, and Cohort 3 assessing set and setting of treatment. Introspect believes that high-quality digital combination therapies have the potential to improve the safety and effectiveness of many mental health treatments. In addition, Introspect considers DTx to be vital to the mission of providing personalized and scalable treatment to those who might not otherwise be able to access high-quality psychological care.


© S&P Capital IQ 2021
All news about ATAI LIFE SCIENCES N.V.
07:01aATAI LIFE SCIENCES N : Launches atai Impact, a Philanthropic Program to Harness the Power ..
AQ
10/18ATAI LIFE SCIENCES N : HC Wainwright Starts Atai Life Sciences at Buy with $40 Price Targe..
MT
10/11ATAI LIFE SCIENCES N : Chymia Form Precision Psychiatry Company to Develop Targeted Depres..
MT
10/11ATAI LIFE SCIENCES N : announces the launch of PsyProtix, to develop a precision psychiatr..
AQ
10/11Atai Life Sciences Announces the Launch of Psyprotix, to Develop A Precision Psychiatry..
CI
10/05Asian ADRs Move Higher in Tuesday Trading
MT
10/01Asian ADRs Sharply Lower Friday as China Education Stocks Slide
MT
09/21ATAI LIFE SCIENCES N : Unit Starts Dosing in Phase 1/2a Trial of Ibogaine in Opioid Use Di..
MT
09/21ATAI LIFE SCIENCES N : DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogain..
AQ
09/15ATAI LIFE SCIENCES N : Increases Loan in Principal by US$6m to Support IntelGenx's Graduat..
AQ
More news
Analyst Recommendations on ATAI LIFE SCIENCES N.V.
More recommendations
Financials (USD)
Sales 2021 18,3 M - -
Net income 2021 -114 M - -
Net cash 2021 383 M - -
P/E ratio 2021 -17,1x
Yield 2021 -
Capitalization 2 166 M 2 166 M -
EV / Sales 2021 97,7x
EV / Sales 2022 23 872x
Nbr of Employees 35
Free-Float 90,3%
Chart ATAI LIFE SCIENCES N.V.
Duration : Period :
Atai Life Sciences N.V. Technical Analysis Chart | ATAI | NL0015000DX5 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 13,99 $
Average target price 30,09 $
Spread / Average Target 115%
EPS Revisions
Managers and Directors
Florian Brand Chief Executive Officer
Gregory L. Weaver Chief Financial Officer
Srinivas G. Rao Chief Scientific Officer
Rolando Gutíerrez-Esteinou Chief Medical Officer
Alexis Marc Joel Louis de Rosnay Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ATAI LIFE SCIENCES N.V.0.00%2 166
MODERNA, INC.220.51%135 157
LONZA GROUP AG27.29%58 232
IQVIA HOLDINGS INC.38.67%47 608
SEAGEN INC.-1.81%31 287
CELLTRION, INC.-39.69%24 952